PPD (NASDAQ:PPD) Releases FY 2021 After-Hours Earnings Guidance

PPD (NASDAQ:PPD) issued an update on its FY 2021
After-Hours earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.37-1.45 for the period, compared to the Thomson Reuters consensus estimate of $1.39. The company issued revenue guidance of $5.145-5.304 billion, compared to the consensus revenue estimate of $5.06 billion.PPD also updated its Q1 2021
After-Hours guidance to 0.30-0.32 EPS.

Shares of PPD traded down $0.25 during mid-day trading on Tuesday, hitting $36.33. The company’s stock had a trading volume of 935,152 shares, compared to its average volume of 864,004. The firm has a 50-day simple moving average of $35.68 and a 200 day simple moving average of $34.61. The firm has a market capitalization of $12.70 billion and a P/E ratio of 238.07. PPD has a 1-year low of $10.61 and a 1-year high of $38.76.

Several analysts have recently commented on PPD shares. Zacks Investment Research raised PPD from a hold rating to a buy rating and set a $39.00 price target for the company in a report on Tuesday, November 17th. Deutsche Bank Aktiengesellschaft raised their price target on PPD from $33.00 to $38.00 and gave the company a buy rating in a report on Thursday, October 29th. Seventeen equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and a consensus target price of $35.06.

In other PPD news, CEO David S. Simmons sold 77,065 shares of the firm’s stock in a transaction on Friday, February 12th. The stock was sold at an average price of $38.01, for a total transaction of $2,929,240.65. Following the completion of the transaction, the chief executive officer now owns 669,999 shares of the company’s stock, valued at $25,466,661.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

PPD Company Profile

PPD, Inc provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services.

Featured Article: Cash Flow Analysis in Stock Selection

Earnings History and Estimates for PPD (NASDAQ:PPD)

Receive News & Ratings for PPD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PPD and related companies with MarketBeat.com's FREE daily email newsletter.